Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma
Zhigang Kang1, Shi-Yong Sun, Liang Cao
1Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin. RMS is classified as embryonal, which is more common in younger children, or alveolar, which is more prevalent in elder children and adults. Despite aggressive management including surgery, radiation, and chemotherapy, the outcome for children with metastatic RMS is dismal, and the prognosis has remained unchanged for decades. Apoptosis is a highly regulated process critical for embryonic development and tissue and organ homeostasis. Like other types of cancers, RMS develops by evading intrinsic apoptosis via mutations in the p53 tumor suppressor gene. However, the ability to induce apoptosis via the death receptor-dependent extrinsic pathway remains largely intact in tumors with p53 mutations. This paper focuses on activating extrinsic apoptosis as a therapeutic strategy for RMS by targeting the death receptor DR5 with a recombinant TRAIL ligand or agonistic antibodies directed against DR5.
Insights
Pediatric rhabdomyosarcoma (RMS) evades apoptosis, but the extrinsic pathway is intact. Targeting the death receptor DR5 offers a promising therapeutic strategy for this challenging childhood cancer.
Area of Science:
- Pediatric Oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Rhabdomyosarcoma (RMS) is the most frequent pediatric soft tissue sarcoma, originating from muscle progenitors.
- Despite multimodal treatment, metastatic RMS in children has a poor prognosis with limited therapeutic advancements.
- RMS cells evade intrinsic apoptosis through p53 mutations, but the extrinsic death receptor pathway remains functional.
Purpose of the Study:
- To investigate the potential of activating the extrinsic apoptosis pathway as a therapeutic strategy for rhabdomyosarcoma.
- To explore targeting the death receptor DR5 as a means to induce cancer cell death in RMS.
Main Methods:
- Focus on activating the extrinsic apoptosis pathway in RMS.
- Utilizing recombinant TRAIL ligand to target the death receptor DR5.
- Employing agonistic antibodies directed against DR5.
Main Results:
- The extrinsic apoptosis pathway, mediated by DR5, remains a viable target in p53-mutated RMS.
- Targeting DR5 can potentially induce apoptosis in RMS cells, offering a novel therapeutic avenue.
Conclusions:
- Activating extrinsic apoptosis by targeting DR5 presents a promising therapeutic strategy for pediatric rhabdomyosarcoma.
- This approach may overcome resistance mechanisms associated with intrinsic apoptosis evasion in RMS.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...